Clinical Efficacy And Safety Of Ticagrelor In Emergency PCI Patients

Background: Antiplatelet therapy is the cornerstone of medical treatment for patients with acute coronary syndrome(ACS).Over the past few years,several new studies in ACS have evaluated the efficacy of new oral or intravenous antiplatelet drugs.The focus of the study is to assess the superiority of various types of pharmacodynamics,and several large-scale random Controlled trials have shown that platelet ADP P2Y12 receptor antagonists(ie prasugrel and ticagrelor)are superior to clopidogrel.In percutaneous coronary intervention(PCI)treatment of clopidogrel in patients with ACS,many studies have observed a high rate of platelet adenosine diphosphate(ADP)reactivity,a significant increase in non-fatal myocardial infarction,clear/possible Stent thrombosis or cardiovascular mortality.Objective: This study was designed to compare the difference between clopidogrel responders and ticagrelor-treated patients after PCI for ACS.The purpose of this study was to evaluate the clinical efficacy of ticagrelor for patients with emergency PCI,to understand the selection of antiplatelet drugs in patients with acute coronary syndromes and to explore the safety in emergency PCI.Method: A total of 164 patients with ACS who were admitted to the Department of Cardiology,Affiliated Qingdao Affiliated Hospital of Qingdao University from June 2015 to March 2017 were included.Among them,96 patients received ticagrelor and 68 patients received clopidogrel.The routine drug treatment.There was no difference in the basic clinical data between the two groups.The following three tests were conducted.Test I: Observe and count information on the patient's gender,body mass index(BMI),smoking,hypertension,diabetes,dyslipidemia,serum creatinine,brain natriuretic peptide,troponin peak,intervention route,etc.;Test II: observe and count Treatment of liver function,renal function,muscle zymogram,platelet inhibition status,blood index and function and other indicators of change in liver function in patients with acute PCI with glycoside and chlor-Gray;trial III: basic statistical data,two groups of patients taking medication After 10,30,90 and 180 days of follow-up,relevant adverse events were recorded,and the platelet aggregation rate(ADP)of the patients detected at 10 days after PCI was recorded.Results: 1.After PCI,there was no significant difference in platelet count between ticagrelor and clopidogrel(P>0.05),The inhibition rates of ADP in the two groups were 48.3 + 2.7 and 42.4 + 2.2 respectively,and the difference was statistically significant(P<0.05);2.Coronary artery blood flow during PCI was significantly lower in TIGI 2 and ticagrelor(17.7%,17/96)than in clopidogrel,39.7%(27/68),and the difference was statistically significant(P<0.05).0.05);3.At 10,30,90,and 180 days after operation,the incidence of major cardiac adverse events in the ticagrelor group was lower than that in the clopidogrel group(P<0.05).4.There were no significant differences between the two groups in major bleeding events and minor bleeding events(P<0.05).Conclusion: The use of ticagrelor before ACS in patients undergoing emergency PCI has good clinical efficacy and the immediate effect during operation and the long-term cardiac benefit after surgery.Conclusion: Preoperative application of ticagrelor in patients undergoing primary PCI for ACS has good clinical efficacy and the effect of the surgery and the long-term cardiac benefit after the operation are apparent.